SCHEMBL4945273

SCHEMBL4945273

COCCNC(=O)c1cc(C(C)S(=O)(=O)O)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.43
HPGD P15428 5/20 0.42
RAB9A P51151 4/20 0.42
LMNA P02545 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LOXL2 Q9Y4K0 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP2C19 P33261 1/20 0.41
EPHX2 P34913 1/20 0.40
CA2 P00918 2/20 0.39
CA4 P22748 2/20 0.39
LOX P28300 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25692508 0.86 HPGD (0.46) TP53HPGDRAB9ALMNAALDH1A1
SCHEMBL171084 0.76 HPGD (0.50) TP53HPGDRAB9ALMNAALDH1A1
Lufironil SCHEMBL344625 0.76 HPGD (0.56) TP53HPGDALDH1A1LOXL2LOX
SCHEMBL4945290 0.76 HPGD (0.47) TP53HPGDRAB9ALMNAALDH1A1
SCHEMBL2324988 0.74 OPRM1 (0.37) MKNK1
SCHEMBL23015733 0.73 RAB9A (0.47) HPGDRAB9ALMNANPC1SMN1; SMN2
SCHEMBL4937449 0.73 LOXL2 (0.46) HPGDRAB9ALMNAALDH1A1CYP1A2
SCHEMBL8842629 0.73 LOXL2 (0.50) TP53HPGDRAB9ALMNAALDH1A1
SCHEMBL18049360 0.73 LOXL2 (0.66) HPGDRAB9ALMNAALDH1A1CYP1A2
Hydrochloric Acid SCHEMBL18049316 0.72 LOXL2 (0.65) HPGDRAB9ALMNAALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents BAYER PHARMACEUTICALS CORPORATION (US) 2008-11-27 US disclosed
EP-1765811-A2 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS Bayer Pharmaceuticals Corporation (US) 2007-03-28 EP disclosed
WO-2006002383-A2 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents ABCC3, HCCS, ABCC2 TP53 390/4885HPGD 2269/4885RAB9A 2779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.